We are live on
!
Find out more
Iovance Biotherapeutics
IOVA
IOVA
286 hedge funds and large institutions have $2.21B invested in Iovance Biotherapeutics in 2024 Q3 according to their latest regulatory filings, with 39 funds opening new positions, 108 increasing their positions, 84 reducing their positions, and 46 closing their positions.
New
Increased
Maintained
Reduced
Closed
80% more funds holding in top 10
Funds holding in top 10: 5 → 9 (+4)
79% more call options, than puts
Call options by funds: $44.1M | Put options by funds: $24.7M
29% more repeat investments, than reductions
Existing positions increased: 108 | Existing positions reduced: 84
19% more capital invested
Capital invested by funds: $1.86B → $2.21B (+$346M)
3% less funds holding
Funds holding: 295 → 286 (-9)
5.59% less ownership
Funds ownership: 83.1% → 77.51% (-5.6%)
15% less first-time investments, than exits
New positions opened: 39 | Existing positions closed: 46
Holders
286
Holders Change
-9
Holders Change %
-3.05%
% of All Funds
4.11%
Holding in Top 10
9
Holding in Top 10 Change
+4
Holding in Top 10 Change %
+80%
% of All Funds
0.13%
New
39
Increased
108
Reduced
84
Closed
46
Calls
$44.1M
Puts
$24.7M
Net Calls
+$19.4M
Net Calls Change
+$12.7M
Top Buyers
Top Sellers
| 1 |
ACA
Avoro Capital Advisors
New York
|
-$70.7M |
| 2 |
Voloridge Investment Management
Jupiter,
Florida
|
-$22.6M |
| 3 |
JP Morgan Chase
New York
|
-$14.6M |
| 4 |
Marshall Wace
London,
United Kingdom
|
-$12.9M |
| 5 |
SPPAM
Summit Partners Public Asset Management
Boston,
Massachusetts
|
-$12.5M |
